{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:04:19Z","timestamp":1767139459005,"version":"build-2238731810"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["104-2314-B-002-164-MY3"],"award-info":[{"award-number":["104-2314-B-002-164-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["103-2314-B-002-161-MY3"],"award-info":[{"award-number":["103-2314-B-002-161-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["103-S2349"],"award-info":[{"award-number":["103-S2349"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["104-M2868"],"award-info":[{"award-number":["104-M2868"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["105-S2978"],"award-info":[{"award-number":["105-S2978"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["105-28"],"award-info":[{"award-number":["105-28"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00109-018-1697-7","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T12:52:59Z","timestamp":1538657579000},"page":"1307-1318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf\/MEK\/ERK pathway in urothelial carcinoma"],"prefix":"10.1007","volume":"96","author":[{"given":"Wei-Chou","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Shun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Lin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shing-Hwa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Tung","family":"Shun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Sheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Chiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chieh","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June-Tai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Ming","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ming","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo-Yu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-How","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"1697_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9\u201329","journal-title":"CA Cancer J Clin"},{"key":"1697_CR2","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1200\/JCO.1985.3.11.1463","volume":"3","author":"WG Harker","year":"1985","unstructured":"Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A northern California oncology group study. J Clin Oncol 3:1463\u20131470","journal-title":"J Clin Oncol"},{"key":"1697_CR3","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","volume":"64","author":"CN Sternberg","year":"1989","unstructured":"Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg L, Rosado K, Smart T, Lin SY, Penenberg D, Fair WR, Whitmore WF (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448\u20132458","journal-title":"Cancer"},{"key":"1697_CR4","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"HSW von der MH","year":"2000","unstructured":"von der MH HSW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068\u20133077","journal-title":"J Clin Oncol"},{"key":"1697_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fonc.2014.00144","volume":"4","author":"DJ Marsh","year":"2014","unstructured":"Marsh DJ, Shah JS, Cole AJ (2014) Histones and their modifications in ovarian cancer\u2014drivers of disease and therapeutic targets. Front Oncol 4:144","journal-title":"Front Oncol"},{"key":"1697_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1667\/RR3308.2","volume":"179","author":"CR Hunt","year":"2013","unstructured":"Hunt CR, Ramnarain D, Horikoshi N, Iyengar P, Pandita RK, Shay JW, Pandita TK (2013) Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat Res 179:383\u2013392","journal-title":"Radiat Res"},{"key":"1697_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cell.2012.08.006","volume":"150","author":"SM Abmayr","year":"2012","unstructured":"Abmayr SM, Workman JL (2012) Holding on through DNA replication: histone modification or modifier? Cell 150:875\u2013877","journal-title":"Cell"},{"key":"1697_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1101\/gad.182014.111","volume":"26","author":"K Kamieniarz","year":"2012","unstructured":"Kamieniarz K, Izzo A, Dundr M, Tropberger P, Ozretic L, Kirfel J, Scheer E, Tropel P, Wisniewski JR, Tora L, Viville S, Buettner R, Schneider R (2012) A dual role of linker histone H1.4 Lys 34 acetylation in transcriptional activation. Genes Dev 26:797\u2013802","journal-title":"Genes Dev"},{"key":"1697_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/ERC-13-0399","volume":"21","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Liu D, Murugan AK, Liu Z, Xing M (2014) Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer 21:161\u2013173","journal-title":"Endocr Relat Cancer"},{"key":"1697_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1:19\u201325","journal-title":"Mol Oncol"},{"key":"1697_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","volume":"6","author":"M New","year":"2012","unstructured":"New M, Olzscha H, La Thangue NB (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6:637\u2013656","journal-title":"Mol Oncol"},{"key":"1697_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124:30\u201339","journal-title":"J Clin Invest"},{"key":"1697_CR13","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-11-3144","volume":"18","author":"HM Prince","year":"2012","unstructured":"Prince HM, Dickinson M (2012) Romidepsin for cutaneous T-cell lymphoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 18:3509\u20133515","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"1697_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12022-014-9345-4","volume":"25","author":"TJ Giordano","year":"2014","unstructured":"Giordano TJ (2014) The cancer genome atlas research network: a sight to behold. Endocr Pathol 25:362\u2013365","journal-title":"Endocr Pathol"},{"key":"1697_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6890-14-10","volume":"14","author":"C Poyet","year":"2014","unstructured":"Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G (2014) Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol 14:10","journal-title":"BMC Clin Pathol"},{"key":"1697_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1479-5876-5-49","volume":"5","author":"MT Buckley","year":"2007","unstructured":"Buckley MT, Yoon J, Yee H, Chiriboga L, Liebes L, Ara G, Qian X, Bajorin DF, Sun TT, Wu XR, Osman I (2007) The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 5:49","journal-title":"J Transl Med"},{"key":"1697_CR17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/CAD.0b013e32834a2c70","volume":"22","author":"S Vallo","year":"2011","unstructured":"Vallo S, Xi W, Hudak L, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA (2011) HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anti-Cancer Drugs 22:1002\u20131009","journal-title":"Anti-Cancer Drugs"},{"key":"1697_CR18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.urolonc.2008.11.018","volume":"28","author":"W Qu","year":"2010","unstructured":"Qu W, Kang YD, Zhou MS, Fu LL, Hua ZH, Wang LM (2010) Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol Oncol 28:648\u2013654","journal-title":"Urol Oncol"},{"key":"1697_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1464-410X.2009.08795.x","volume":"105","author":"A Ozawa","year":"2010","unstructured":"Ozawa A, Tanji N, Kikugawa T, Sasaki T, Yanagihara Y, Miura N, Yokoyama M (2010) Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int 105:1181\u20131186","journal-title":"BJU Int"},{"key":"1697_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.juro.2015.02.2918","volume":"194","author":"DR Li","year":"2015","unstructured":"Li DR, Zhang H, Peek E, Wang S, Du L, Li G, Chin AI (2015) Synergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancer. J Urol 194:547\u2013555","journal-title":"J Urol"},{"key":"1697_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.juro.2010.10.034","volume":"185","author":"CY Yoon","year":"2011","unstructured":"Yoon CY, Park MJ, Lee JS, Lee SC, Oh JJ, Park H, Chung CW, Abdullajanov MM, Jeong SJ, Hong SK, Byun SS, Lee ES, Lee SE (2011) The histone deacetylase inhibitor trichostatin a synergistically resensitizes a cisplatin resistant human bladder cancer cell line. J Urol 185:1102\u20131111","journal-title":"J Urol"},{"key":"1697_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.taap.2015.11.007","volume":"290","author":"BW Yeh","year":"2016","unstructured":"Yeh BW, Li WM, Li CC, Kang WY, Huang CN, Hour TC, Liu ZM, Wu WJ, Huang HS (2016) Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor. Toxicol Appl Pharmacol 290:98\u2013106","journal-title":"Toxicol Appl Pharmacol"},{"key":"1697_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ijc.2910110327","volume":"11","author":"J Bubenik","year":"1973","unstructured":"Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J (1973) Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 11:765\u2013773","journal-title":"Int J Cancer"},{"key":"1697_CR24","doi-asserted-by":"publisher","first-page":"16948","DOI":"10.1038\/srep16948","volume":"5","author":"IL Ho","year":"2015","unstructured":"Ho IL, Kuo KL, Liu SH, Chang HC, Hsieh JT, Wu JT, Chiang CK, Lin WC, Tsai YC, Chou CT, Hsu CH, Pu YS, Shi CS, Huang KH (2015) MLN4924 synergistically enhances cisplatin-induced cytotoxicity via JNK and Bcl-xL pathways in human urothelial carcinoma. Sci Rep 5:16948","journal-title":"Sci Rep"},{"key":"1697_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27\u201355","journal-title":"Adv Enzym Regul"},{"key":"1697_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1158\/1535-7163.MCT-04-0297","volume":"4","author":"SS Sridhar","year":"2005","unstructured":"Sridhar SS, Hedley D, Siu LL (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4:677\u2013685","journal-title":"Mol Cancer Ther"},{"key":"1697_CR27","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.4161\/cc.9.9.11483","volume":"9","author":"SL Abrams","year":"2010","unstructured":"Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Basecke J, Stivala F, Donia M, Nicoletti F, Libra M et al (2010) The Raf\/MEK\/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9:1781\u20131791","journal-title":"Cell Cycle"},{"key":"1697_CR28","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A et al (2007) Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263\u20131284","journal-title":"Biochim Biophys Acta"},{"key":"1697_CR29","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","volume":"24","author":"AH Jebar","year":"2005","unstructured":"Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24:5218\u20135225","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1007\/s00109-019-01748-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000}}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-018-1697-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-018-1697-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-018-1697-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T04:52:21Z","timestamp":1662180741000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-018-1697-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1697"],"URL":"https:\/\/doi.org\/10.1007\/s00109-018-1697-7","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]},"assertion":[{"value":"30 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In Fig. 1b, upper part, the cell viability counts after treatment with cisplatin and TSA in T24 cells was by mistake a duplication of the image for NTUB1 on the left. In the corrected version of Fig. 1, the image was replaced appropriately.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In Fig. 1b, upper part, the cell viability counts after treatment with cisplatin and TSA in T24 cells was by mistake a duplication of the image for NTUB1 on the left. In the corrected version of Fig. 1, the image was replaced appropriately.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study that involve human participants and animal experiments have been approved by the institutional research ethics committee (no. 201112136RIC) and National Taiwan University College of Medicine and College of Public Health Institutional Animal Care and Use Committee (IACUC) (No. 20160117).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}